The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Open accessAbstract
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival (OS). In addition, global phase III studies investigating secondline therapy with brivanib [6] , everolimus [7] , and ramucirumab [8] , and a regional trial investigating S-1 (tegafur/gimeracil/oteracil) in Japan, were unsuccessful ( Table 1 ). Thus, sorafenib was the only systemic therapeutic agent available for HCC, and for some time no options were available for patients with progressive disease or those intolerant to sorafenib. However, between June 2016 and January 2017, promising results of global phase III studies were reported. The results of a trial of regorafenib were reported at a conference [9] and in a journal [10] , and results with lenvatinib were reported in a press release [11] , indicating the arrival of a new era of liver cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Self-citationZhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Self-citationCheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Self-citationJohnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Self-citationCainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Self-citationLlovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Self-citationKudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.-Y., Takayama, T., Yoon, J.-H., Hori, T., Kumada, H., Hayashi, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.007 · Cited by 570
Self-citationZhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Self-citationKudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J.-F., Yan, L., Yang, J., Lu, L., Tak, W.-Y., Yu, X., et al. (2014) · Hepatology · doi:10.1002/hep.27290 · Cited by 355
Self-citationPhase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
Self-citationTransarterial Chemoembolization Failure/Refractoriness: JSH-LCSGJ Criteria 2014 Update
Kudo, M., Matsui, O., Izumi, N., Kadoya, M., Okusaka, T., Miyayama, S., Yamakado, K., Tsuchiya, K., Ueshima, K., Hiraoka, A., et al. (2014) · Oncology · doi:10.1159/000368142 · Cited by 283
Self-citationKudo, M., Arizumi, T., Ueshima, K., Sakurai, T., Kitano, M., & Nishida, N. (2015) · Digestive Diseases · doi:10.1159/000439290 · Cited by 225
Self-citationArizumi, T., Ueshima, K., Minami, T., Kono, M., Chishina, H., Takita, M., Kitai, S., Inoue, T., Yada, N., Hagiwara, S., et al. (2015) · Liver Cancer · doi:10.1159/000367743 · Cited by 207
Self-citationSurgical and Locoregional Therapy of HCC: TACE
Tsurusaki, M., & Murakami, T. (2015) · Liver Cancer · doi:10.1159/000367739 · Cited by 201
Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan
Kudo, M. (2015) · Liver Cancer · doi:10.1159/000367727 · Cited by 198
Self-citationImmune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
Kudo, M. (2017) · Oncology · doi:10.1159/000451016 · Cited by 194
Self-citationOgasawara, S., Chiba, T., Ooka, Y., Kanogawa, N., Motoyama, T., Suzuki, E., Tawada, A., Kanai, F., Yoshikawa, M., & Yokosuka, O. (2014) · Oncology · doi:10.1159/000365993 · Cited by 180
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
Kudo, M., Izumi, N., Sakamoto, M., Matsuyama, Y., Ichida, T., Nakashima, O., Matsui, O., Ku, Y., Kokudo, N., Makuuchi, M., et al. (2016) · Liver Cancer · doi:10.1159/000367775 · Cited by 143
Self-citationMolecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives
Kudo, M. (2016) · Liver Cancer · doi:10.1159/000452138 · Cited by 78
Self-citationArizumi, T., Ueshima, K., Chishina, H., Kono, M., Takita, M., Kitai, S., Inoue, T., Yada, N., Hagiwara, S., Minami, Y., et al. (2014) · Oncology · doi:10.1159/000368143 · Cited by 55
Self-citationLocoregional Therapy for Hepatocellular Carcinoma
Obi, S., Sato, S., Kawai, T., Ichikawa, S., Ichikawa, T., Motosugi, U., Sano, K., Morisaka, H., Enomoto, N., Matsuda, M., et al. (2015) · Liver Cancer · doi:10.1159/000367741 · Cited by 54
Ho, M., Hasegawa, K., Chen, X., Nagano, H., Lee, Y.-J., Chau, G., Zhou, J., Wang, C.-C., Choi, Y. R., Poon, R. T. P., et al. (2016) · Liver Cancer · doi:10.1159/000449335 · Cited by 47
Self-citationArizumi, T., Ueshima, K., Iwanishi, M., Minami, T., Chishina, H., Kono, M., Takita, M., Kitai, S., Inoue, T., Yada, N., et al. (2016) · Digestive Diseases · doi:10.1159/000448834 · Cited by 27
Self-citationThyroid Patient Salivary Radioiodine Transit and Dysfunction Assessment Using Chewing Gums
Okkalides, D. (2016) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2076 · Cited by 6
Eskiyurt, N., Sarıdoğan, M. E., Şenel, K., Günaydın, R., Erdal, A., Akarırmak, Ü., Şendur, Ö. F., Barut, K., Akyüz, G., Özsoy, T., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-eular.5374 · Cited by 3
Cited by
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Self-citationBCLC strategy for prognosis prediction and treatment recommendation: the 2022 update
Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.018 · Cited by 4,319
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
Johnson, P. J., Berhane, S., Kagebayashi, C., Satomura, S., Teng, M., Reeves, H. L., O'Beirne, J., Fox, R., Skowronska, A., Palmer, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9151 · Cited by 2,783
Metadata
- Authors
- Kudo, M.
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 6
- Issue
- 3
- Pages
- 177-184
- ISSN
- 2235-1795
- 1664-5553
- OpenAlex
- W2591655368
- Cited by
- 5,936
- References
- 27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.